NCT00184028

Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck

Phase II Trial of Taxotere and Oxaliplatin Combination Chemotherapy in Squamous Cell Carcinoma of the Head and Neck

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University of Southern California · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is for subjects with squamous cell cancer of the head and neck which is not solely treatable with surgery or radiation. This research study involves treatment with an experimental chemotherapy combination of oxaliplatin and Taxotere. Tha main purpose of this study is to assess the effectiveness of this combination of medications for this type of cancer. Approximately 54 subjects will take part in this study.

Conditions

• Carcinoma of the Head and Neck

Interventions

Type	Name	Description
DRUG	Taxotere	Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
DRUG	Oxaliplatin	Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.

Timeline

• Start date: 2004-09-01
• Primary completion: 2009-07-01
• Completion: 2010-07-01
• First posted: 2005-09-16
• Last updated: 2014-05-22
• Results posted: 2013-05-06

Locations

1 site across 1 country: United States